文献速递骨质疏松与钙磷/甲状旁腺

甲状旁腺腺瘤中钙敏感受体(CaSR)表达降低受表观遗传调控

Reduced Calcium Sensing Receptor (CaSR) Expression Is Epigenetically Deregulated in Parathyroid Adenomas.
PubMed 文献 · J Clin Endocrinol Metab · 2020-01-01

研究比较40例散发性甲状旁腺腺瘤与10例对照甲状旁腺组织中CaSR的表达及表观遗传修饰,发现腺瘤中CaSR mRNA表达降低(倍数减少0.12,P<0.0001),90%(36/40)腺瘤蛋白表达降低,启动子2区高甲基化占45%(18/40)较对照6.7%(1/10)显著(P<0.002),H3K9me3富集增加10倍并与CaSR mRNA相关(r=0.61,P<0.003),5-aza-2'脱氧胞苷可恢复甲状旁腺细胞系CaSR表达;作者认为启动子2高甲基化及H3K9me3增加参与散发性甲状旁腺腺瘤中CaSR沉默。

要点

  • 散发性甲状旁腺腺瘤中CaSR mRNA表达降低,倍数减少0.12(P<0.0001)。
  • 90%(36/40)腺瘤CaSR蛋白表达降低。
  • 45%(18/40)腺瘤CaSR启动子2区高甲基化,对照为6.7%(1/10)。

核心结论

  • 作者认为CaSR启动子2区高甲基化及H3K9me3增加参与散发性甲状旁腺腺瘤中CaSR表达的沉默。

研究设计与样本

  • 研究纳入40例散发性甲状旁腺腺瘤和10例对照甲状旁腺组织。
  • 采用实时定量PCR检测CaSR mRNA,免疫组化检测CaSR蛋白表达。
  • 采用亚硫酸氢盐测序分析经亚硫酸氢钠转化的DNA以确定CaSR启动子2区甲基化状态。
  • 采用染色质免疫沉淀-qPCR检测组蛋白修饰在CaSR调控中的作用。

主要发现

  • 实时定量PCR显示甲状旁腺腺瘤中CaSR mRNA表达降低,倍数减少0.12(P<0.0001)。
  • 免疫组化显示90%(36/40)腺瘤中CaSR蛋白表达降低。
  • 与对照(6.7%;1/10)相比,45%(18/40)腺瘤CaSR启动子2区显示显著高甲基化(P<0.002)。
  • 亚硫酸氢盐测序显示CaSR启动子2区胶质细胞缺失2结合位点的CpG甲基化程度最高。
  • 甲状旁腺腺瘤患者中CaSR甲基化状态与血浆完整甲状旁腺激素水平直接相关。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIM: Reduced calcium sensing receptor (CaSR) expression has been implicated in parathyroid tumorigenesis, but the underlying mechanism remains elusive. Accordingly, we aimed to explore the epigenetic changes (DNA methylation and histone modifications) involved in CaSR regulation in sporadic parathyroid adenomas and correlate epigenetic state with disease indices. EXPERIMENTAL DESIGN: Forty sporadic parathyroid adenomas and 10 control parathyroid tissues were studied. Real-time quantitative PCR (qPCR) for mRNA and immunohistochemistry for protein expression of CaSR were performed. The methylation status of the CaSR promoter 2 was determined by bisulphite sequencing analysis of sodium bisulphite-converted DNA. To determine the role of histone modifications in the CaSR regulation, chromatin immunoprecipitation-qPCR assay was performed. RESULTS: Real-time qPCR revealed reduced CaSR mRNA expression with a fold reduction of 0.12 (P < 0.0001) in parathyroid adenomas. Immunohistochemistry revealed reduced protein expression of CaSR in 90% (36/40) of adenomas. The promoter 2 region of CaSR displayed significant hypermethylation in 45% (18/40) of the adenomas compared with the controls (6.7%; 1 of 10) (P < 0.002). Bisulphite sequencing analysis revealed maximum methylated CpG at glial cell missing 2 binding site on the CaSR promoter 2 compared to other CpG sites. The methylation status of CaSR correlated directly with plasma intact parathyroid hormone levels in patients with parathyroid adenoma. With chromatin immunoprecipitation-qPCR analysis, H3K9me3 levels showed increased enrichment by 10-fold in adenomas and correlated with CaSR-mRNA expression (r = 0.61; P < 0.003). Treatment with 5-aza-2'deoxycytidine restored the expression of CaSR in a parathyroid cell line. CONCLUSION: Our data suggest that hypermethylation and increased H3K9me3 of the CaSR promoter 2 are involved in silencing CaSR expression in sporadic parathyroid adenoma.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Singh P, Bhadada SK, Dahiya D, et al. Reduced Calcium Sensing Receptor (CaSR) Expression Is Epigenetically Deregulated in Parathyroid Adenomas. J Clin Endocrinol Metab. 2020. PMID: 32609827. doi:10.1210/clinem/dgaa419

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。